# JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

> **NCT05174585** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** JAB-BX102 (anti-CD73 monoclonal antibody)
- **BIOLOGICAL:** pembrolizumab (anti-PD-1 monoclonal antibody)

## Key facts

- **NCT ID:** NCT05174585
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-18
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174585, "JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05174585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*